©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Dithiocarbamates Trigger Differentiation and Induction of CD11c Gene through AP-1 in the Myeloid Lineage (*)

(Received for publication, December 29, 1995; and in revised form, February 23, 1996)

Julián Aragonés (1)(§) Cristina López-Rodríguez (1)(§) Angel Corbí (2) Pablo Gómez del Arco (3)(¶) Manuel López-Cabrera (1) Manuel O. de Landázuri (1) Juan Miguel Redondo (3)(**)

From the  (1)Servicios de Inmunología y Biología Molecular del Hospital de la Princesa, Madrid, (2)Instituto López Neyra, CSIC, Granada, and (3)Centro de Biología Molecular, CSIC-UAM, Cantoblanco, Madrid, Spain

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

It has recently been shown that the alteration of the cell-redox status affects the transcription factor expression and activity. Dithiocarbamates (DTCs) are potent antioxidant agents that can switch the expression of genes dependent on the activation of the transcription factors AP-1 and NFkappaB. In this study, we show that these agents triggered the expression of genes involved in myeloid differentiation of the promonocytic U-937 cell line. DTCs promoted differentiation-associated changes that included the surface up-regulation of beta2-integrins (CD11a-c/CD18), cell growth arrest concomitant with transferrin receptor (CD71) down-modulation, induction of the nonspecific esterase enzyme, and a rapid drop in the mRNA levels of c-myc. A further analysis, focused on the molecular mechanisms leading to the activation of CD11c expression, revealed that the pyrrolidine derivative of DTC (PDTC) increased CD11c mRNA levels and augmented its gene promoter activity. Transfection experiments with reporter constructs harboring different promoter regions of CD11c gene, indicated the presence of a functional DTC-responsive region located between positions -160 and +40 of the promoter. Gel retardation assays revealed that the PDTC-induced DNA-protein complexes were restricted to members of the Fos and Jun families that bound to an AP-1 site located at position -60 from the transcription start site. A role for this site was confirmed by in vitro mutagenesis experiments that indicated the functional importance of this site for the CD11c gene transcriptional activation in response to PDTC. The effect of DTCs on myeloid cell differentiation supports a possible role for these agents in the therapy of some bone marrow-derived malignancies.


INTRODUCTION

Differentiation of myeloid cells is a complex process that involves the regulated expression of an array of genes responsible for a series of cellular changes that drive precursor cells to different functional and phenotypic cell stages. Several leukemic cell lines arrested at different steps of the myeloid differentiation program, such as the human U-937 and HL-60 cell lines (Sundström and Nilsson, 1976; Collins, 1987), have widely been used to dissect the molecular events accompanying this process. A variety of differentiation inducers such as phorbol esters, 1,25-dihydroxyvitamin D(3), interferon-, and tumor necrosis factor-alpha have been employed to drive these leukemic cell lines toward the macrophage differentiation pathways (Hass et al., 1989; Dood et al., 1983; Ralph et al., 1983; Schütze et al., 1988). During this process, the expression of adhesion molecules implicated in intercellular and cellular-extracellular matrix interactions is tightly regulated (Hynes, 1992). Thus, the expression of different members of adhesion receptors, such as the components of the beta2 leukocyte integrins subfamily LFA-1 (CD11a/CD18; alphaL/beta2), Mac-1 (CD11b/CD18; alphaM/beta2), and p150,95 (CD11c/CD18; alphaX/beta2), together with the member of the immunoglobulin superfamily ICAM-1 (CD54), are up-regulated, whereas VLA-4 (CD49/CD29, alpha4beta1), a member of the beta1 integrin subfamily, is typically down-regulated during differentiation (Miller et al., 1986; Dustin et al., 1986; Ferreira et al., 1991). Other cell surface molecules such as the transferrin receptor (CD71) are also down-modulated (Hass et al., 1989). Additional changes commonly linked with myeloid differentiation and often interrelated are cell growth arrest and changes in the expression of the c-myc proto-oncogene. Thus, the HL-60 and U-937 cell lines exhibit high basal levels of c-myc which are thought to be involved in the high proliferation rate of these cells (Collins, 1987; Cotter et al., 1994). A drop in the c-myc levels, accompanied by cell growth arrest, takes place when cells are induced to differentiate with a variety of agents, which appears to occur in normal bone marrow myeloid progenitors undergoing terminal differentiation (Collins, 1987; Rius et al., 1990).

Recently, reactive oxygen intermediates (ROIs) (^1)such as H(2)O(2), superoxide (O(2)), and hydroxyl radical (OH), have been described as common signal transduction mediators in a number of activation pathways. The involvement of these intermediates in such processes has been analyzed on the basis of their effects on the activities of the transcription factors NFkappaB and AP-1. Thus, NFkappaB behaves as an oxidative-stress responsive factor that can be directly activated by H(2)O(2) (Schreck et al., 1991; Meyer et al., 1993) or through stimuli that increase intracellular ROIs levels (Schreck et al., 1992b). These prooxidant stimuli can also induce AP-1 activation as in the case of UV light and H(2)O(2) (Devary et al., 1991), proinflammatory cytokines (Brenner et al., 1989; Muñoz et al., 1992) and -radiation (Datta et al., 1992). Strikingly, whereas the activation of NFkappaB can be prevented by several antioxidant compounds with ROIs scavenging properties, including DTCs (Meyer et al., 1993; Schenk et al., 1994; Schreck et al., 1992a; Staal et al., 1990), these agents per se induce both AP-1 DNA binding activity and AP-1-dependent transcriptional activation by mechanisms that involve de novo transcription of c-fos and c-jun (Meyer et al., 1993; Schenk et al., 1994). An additional redox mechanism that modulates AP-1 activity is based on the presence of a critical redox-sensitive cysteine residue that regulates the DNA binding of Fos and Jun proteins (Abate et al., 1990). Strikingly, AP-1 is activated early on when an antioxidative state is induced in cells under hypoxic conditions (Yao et al., 1994). Hence, AP-1 can be activated by signals generated under prooxidant and antioxidant conditions.

Cellular differentiation is mainly regulated by selective expression of genes largely controlled at the transcriptional level. Since AP-1 can behave as an antioxidant-responsive transcription factor and exogenous antioxidants can potentially switch on genes through the activation of this transcription factor, we analyzed herein whether the DTCs affect the expression of genes involved in myeloid differentiation. Interestingly, we found that DTCs trigger the expression of myeloid differentiation antigens, as well as other changes associated to the differentiation of U-937 cells. To characterize the molecular mechanisms involved in this process, we analyzed the effect of these agents on the transcription of p150,95 alpha-subunit (CD11c) gene. This analysis indicated that DTCs stimulate CD11c gene promoter and identified the transcription factor AP-1 as a central target implicated in this activation.


EXPERIMENTAL PROCEDURES

Cell Culture and Reagents

The human promonocytic U-937, and the HL-60 promyelocytic cell lines were grown in RPMI 1640 with GLUTAMAX-I (Life Technologies, Inc.) supplemented with 10% of fetal calf serum. Pyrrolidine dithiocarbamate (PDTC), diethyl dithiocarbamate (DDTC), disulfiram and phorbol 12-myristate 13-acetate (PMA) were purchased from Sigma. The protein kinase C inhibitor bisindolylmaleimide (Toullec et al., 1991) was from Calbiochem-Novabiochem Corp., La Jolla, CA.

Antibodies, Flow Cytometry Analysis, and Cytochemical Staining

RR1/1 IgG1 mAb (anti-CD54) was a kind gift of Dr. R. Rothlein (Boëhringer Ingelheim). TS1/11 mAb (anti-CD11a), Bear 1 mAb (anti-CD11b), HC1/1 mAb (anti-CD11c), HP2/4 mAb (anti-CD49d), and FG2/12 mAb (anti-CD71) have previously been described (Cabañas et al., 1989, 1990; López Guerrero et al., 1989; Pulido et al., 1992).

Flow cytometry analysis was performed as described previously (Postigo et al., 1991). Briefly, after different treatments, cells were collected by centrifugation, resuspended in phosphate-buffered saline, and incubated for 30 min with 100 µl (1 µg) of purified RR1/1 or 100 µl of the hybridoma culture supernatants indicated above. Antibodies were incubated in the presence of 50 µg/ml -globulin to prevent binding through the Fc portion of the antibodies. Cells were washed, and bound antibodies were detected using fluorescein isothiocyanate-conjugated rabbit F(ab)`2 anti-mouse IgG (Dako A/S, Denmark), and finally resuspended in 300 µl of propidium iodide (2 ng/µl). The supernatant from the myeloma P3X63 was included as a negative control. Samples were analyzed by flow cytometry in a fluorescein-activated cell sorter cytofluorometer (Becton Dickinson, Mountain View, CA). Analysis was performed over viable cells (typically higher than 95%) as determined by staining with the fluorochrome propidium iodide. Cell proliferation was determined by counting in a hematocytometer the number of viable cells by trypan blue exclusion.

For cytochemical staining, 10^5 cells were centrifuged in a Cytospin (Shandon, Shandon Southern Products Ltd.) over microscope slides and stained for the detection of the nonspecific esterase (NSE) following the instructions of a NSE kit (Sigma). Cell preparations were observed in a Nikon Labophot-2 photomicroscope, and more than 300 cells were counted to score the proportion of strongly positive stained cells.

RNA Analysis

Cells were incubated with different concentrations of PDTC or PMA and harvested after various time points. Total cellular RNA was isolated from each sample by using either the guanidinium isothiocyanate-CsCl ultracentrifugation method (Sambrook et al., 1989) or the Ultraspec system (Biotecx Laboratories, Inc.). Denaturated RNA (5-10 µg) was blotted onto nitrocellulose membranes following the instructions of Bio-Dot® SF Microfiltration Apparatus (Bio-Rad). After UV cross-linking, the filters were hybridized with the following specific probes: a 0.8-kb PstI fragment from the CD11c cDNA (Corbíet al., 1987), a 1.4-kb HindIII-EcoRI fragment from c-myc cDNA, a 0.8-kb BglII-NcoI fragment from the c-fos cDNA, a 0.8-kb HindIII-PstI fragment from the c-jun cDNA, and a 0.6-kb HindIII-BamHI fragment of the beta-actin cDNA for comparative purposes.

Plasmids, Transfections, and Analysis of Luciferase Activity

The luciferase gene-derived plasmid constructs containing the nested deletion fragments of the CD11c promoter spanning from nucleotides -361 to +40, -253 to +40, -160 to +40 have previously been described (López-Cabrera et al., 1993). The mutated plasmids pCD11C361(-60mut)-Luc and pCD11C160(-60mut)-Luc have been described elsewhere. (^2)Briefly, mutation of the AP-1 site (-61 to -54) was achieved by replacing the core AP-1 consensus sequence 5`-CTGACTCA-3` for the PstI-containing sequence 5`-CTGCAGCA-3`, generating the mutated pCD11C361(-60 mut)-Luc plasmid. From this plasmid, pCD11C160 (-60mut)-Luc was generated by a polymerase chain reaction.

For transfection experiments, a total of 35 times 10^6 U-937 cells were electroporated with 50 µg of the different constructs, as described previously (López-Cabrera et al., 1993), and cultured either in the absence or presence of PDTC, 50 µM, or PMA, 20 ng/ml. After 13 h, cells were collected by centrifugation, and luciferase activity was quantified following instructions described in a luciferase assay kit (Promega, Madison, WI). To determine transfection efficiency, 12 µg of pCMVbeta-gal (Clontech Laboratories Inc., Palo Alto, CA), which contains the cytomegalovirus promoter upstream to the beta-galactosidase gene, were included in each transfection. beta-Galactosidase activity was measured following the protocol previously described (Sambrook et al., 1989).

Nuclear Extracts

Small scale nuclear extracts from untreated or PDTC-treated U-937 cells were obtained as described previously (Osborn et al., 1989) with some modifications. Briefly, cells were collected by centrifugation and washed once with phosphate-buffered saline and twice with buffer A (10 mM Hepes, pH 7.9, 1.5 mM MgCl(2), 10 mM KCl, 0.5 mM dithiothreitol). The cell pellet was then resuspended in buffer A, 0.1% Nonidet P-40, and incubated for 10 min. Lysed cells were microcentrifuged, and nuclear pellet was extracted with 3 volumes of buffer C (20 mM Hepes pH 7.9, 25% v/v glycerol, 0.4 M KCl, 1.5 mM MgCl(2), 0.2 mM EDTA) in the presence of dithiothreitol and protease inhibitors. Nuclear pellet volume was estimated to correct the final KCl concentration to 400 mM. After 30 min of incubation, nuclei were microcentrifuged for 30-45 min, and the supernatant was diluted with 4 volumes of modified buffer D (20 mM Hepes pH 7.9, 20% v/v glycerol, 50 mM KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol) (Osborn et al., 1989), and frozen at -70 °C. All steps were performed on ice. Protein concentrations were determined by Bradford assay.

Electrophoretic Mobility Shift Assays (EMSAs)

Gel retardation assays were performed as described (Redondo et al., 1991) with minor modifications. A total of 2 µg of nuclear protein were incubated with 1 µg of poly(dI-dC) DNA carrier, 2.5 µl of 5 times DNA binding buffer (polyvinylethanol, 10% w/v; glycerol, 12.5% v/v; 50 mM Tris, pH 8.0, EDTA, 2.5 mM; dithiothreitol, 2.5 mM) in a final volume of 10.5 µl for 10 min on ice. The incubation was performed in the presence or absence of 30-fold molar excess of homologous unlabeled oligonucleotide. Then 5 times 10^4 cpm (5 times 10^7 cpm/µg) of P-labeled double-stranded oligonucleotides (2 µl) were added and incubated at room temperature for 20 min. DNA-protein complexes were resolved from free probe using a 4% polyacrylamide gel in TBE buffer. The serological characterization of the AP-1 complex resolved by EMSA was performed by incubating the antisera (1 µl) and the nuclear extracts prior to the addition of labeled oligonucleotides. The rabbit antisera used against Fos family (RR26/8) and Jun family (6 36/6) members were kindly provided by Dr. Rodrigo Bravo (Bristol-Myers Squibb, Princeton, NJ).

Oligonucleotides (and their complementaries) from the CD11c gene promoter used as probes in EMSAs contained the following sequences: 5`-GCCCCCTCTGACTCATGCTGAC4-3` (nucleotides -68 to -46) (probe A); 5`-GACTCCGGTTGGGGGGTGGGGGCGTGTGGGAGCCGAGC-3` (nucleotides -136 to -99) (probe B); 5`-GCGTACTCTGCCCGCCCCCTCTGACTC-3` (nucleotides -81 to -55) (probe C); 5`-TCCTTCCCCTGGCCACCTCTCTGCCCACTTG-3` (nucleotides -39 to -8) (probe D); 5`-TGCTGACAATCTTCTTCCTTCCCCTGGCCAC-3` (nucleotides -54 to -23) (probe E); 5`-TCTGCCCACTTGCTTCCTCAGTACCTTGGT-3` (nucleotides -19 to +11) (probe F); and 5`-GGGAGCCGAGCCTGTCCTCGGATCAGTTG-3` (nucleotides -109 to -81) (probe G). Complementary double-stranded oligonucleotides were annealed and labeled using avian myeloblastosis virus reverse transcriptase.


RESULTS

Differentiation-associated Changes Induced by Dithiocarbamates in U-937 Cell Line

Promonocytic U-937 cells can be induced to differentiate toward macrophages in the presence of phorbol esters (Minta and Pambrum, 1985). During this process, a regulated expression of important cell surface molecules takes place. To explore the effects of DTCs on U-937 differentiation, these cells were treated with 50 µM of PDTC for 24 h, and changes in the expression of a number of differentiation markers were analyzed by flow cytometry. PDTC treatment results in up-regulation of cell surface expression of integrins beta2 (CD11a-c/CD18) and ICAM-1 (CD54), and down-modulation of the beta1 integrin VLA-4 (CD49d/CD29) and the transferrin receptor (CD71). These changes were qualitatively similar to those elicited by PMA (Fig. 1A) (Miller et al., 1986; Dustin et al., 1986; Ferreira et al., 1991; Hass et al., 1989). Furthermore, other DTCs, such as DDTC and its disulfide-linked form, disulfiram, induced a cell surface antigen expression pattern comparable to that triggered by PDTC in the U-937 cell line (Fig. 1B), as well as in the promyelocytic HL-60 cell line (data not shown).


Figure 1: Flow cytometry profiles of differentiation markers induced by dithiocarbamates. A, surface expression of the antigens indicated was analyzed by flow cytometry on either untreated U-937 cells or treated for 24 h with PMA, 20 ng/ml, or PDTC, 50 µM. B, effects of DDTC and disulfiram. Both DTCs were incubated for 24 h at doses of 50 and 20 µM, respectively. The monoclonal antibodies used were TS1/11 (anti-CD11a), Bear-1 (anti-CD11b), HC1/1 (anti-CD11c), RR1/1 (anti-CD54), HP2/4 (anti-CD49d), and FG2/12 (anti-CD71). Dotted and solid lines indicate the profiles of untreated and treated cells, respectively.



Since cell surface changes induced by dithiocarbamates in U-937 and HL-60 cells were characteristic of differentiation processes, we performed experiments directed to determine whether DTCs exerted additional changes associated to the myeloid differentiation program using PDTC. The appearance of the acid alpha-naphthyl acetate esterase (nonspecific esterase) enzymatic activity is a typical marker of myeloid differentiation toward monocyte-macrophages cells induced by PMA (Rovera et al., 1979; Collins, 1987). Cytochemical experiments performed in U-937 revealed that PDTC significantly induced the expression of NSE at 24 h (Fig. 2A), although to lower extent than that elicited by PMA (data not shown). At this time, treatment with the antioxidant produced cell growth inhibition at doses as low as 20 µM, being maximal with concentrations ranging from 35 to 50 µM (Fig. 2A). Additionally, dot blot experiments revealed that the levels of c-myc RNA markedly declined after 6 h of treatment with 100 µM of PDTC and remained at undetectable levels by 16 h, as occurred with PMA (Fig. 2B). At lower doses of DTC, c-myc levels were also down-modulated after 6 h, and later reinduced (data not shown). Altogether, these results demonstrate that PDTC not only induces cell surface differentiation markers but also affects the proliferation of U-937 cells as well as other differentiation-associated events.


Figure 2: Effects of PDTC on cell growth, nonspecific esterase staining, and c-myc RNA levels in U-937 cells. A, cells were treated with different doses of PDTC for 24 h and processed for alpha-naphthyl acetate esterase (NSE) staining. Percents of strongly stained cells and cell growth are represented. Cell number was determined by seeding 3 times 10^5 cells in the presence and the absence of PDTC at the concentrations indicated. After 24 h, cells were counted in a hematocytometer. Cell viability, determined by trypan blue exclusion, was higher than 95% for the different treatments. B, dot blot analysis was performed with total RNA isolated from cells untreated or treated with PMA, 20 ng/mL, and PDTC, 100 µM, for 6 or 16 h. RNA was hybridized with cDNA probes of the human c-myc and beta-actin genes.



Since PDTC exerted similar differentiation-associated changes than those triggered by PMA, we performed experiments to determine whether protein kinase C (PKC) was mediating the effect of PDTC. As expected, treatment of the cells with the PKC-specific inhibitor bisindolylmaleimide resulted in a dramatic inhibition of CD11c and CD54 surface expression induced by PMA. By contrast, the induction of these markers by PDTC remained unaffected in the presence of the same concentrations of the inhibitor (Fig. 3). Furthermore, microscopic examination of cultures of U-937 cells revealed additional differences in the signals displayed by both inducers. Thus, PMA-mediated differentiation was accompanied with strong cell-aggregation and cell adherence to plastic surfaces, whereas PDTC, failed to induce such changes (not shown). These data indicate that the signaling pathway triggered by the dithiocarbamate is not dependent on PKC activity and differs from that elicited by PMA.


Figure 3: Effects of the PKC inhibitor bisindolylmaleimide on CD11c and CD54 expression induced by PDTC and PMA. U-937 cells were pretreated or not for 2 h with the inhibitor (2 µM) before addition of PDTC (50 µM) or PMA (20 ng/ml). After 24 h cells were analyzed for surface expression markers by fluorescein-activated cell sorter analysis. Dotted lines indicate profiles of untreated cells and solid lines represent the profiles of treated cells as indicated.



Effect of PDTC on CD11c Gene Transcription

The expression of the integrin p150,95 (CD11c/CD18), a marker of myeloid differentiation, is regulated during the myeloid development (Hogg et al., 1986; Miller et al., 1986). Previous works have demonstrated that the transcriptional activation of alpha-subunit (CD11c)-encoding gene directs the expression of the CD11c/CD18 heterodimer during PMA-induced differentiation (Bellón et al., 1994; López-Cabrera et al., 1993). To search for the mechanisms responsible for the phenotypic changes induced by DTCs, we analyzed their effect on the expression of CD11c-encoding gene. Dot blot analysis revealed that in PDTC-treated cells CD11c mRNA levels increased after 6 h of incubation, and reached its highest levels between 16 and 24 h (Fig. 4A). PMA, which induced a stronger surface expression of the p150,95 molecule, also triggered a higher mRNA induction (Bellón et al., 1994) (data not shown).


Figure 4: Transcriptional response of CD11c gene to PDTC. A, Dot blot analysis was performed with total RNA isolated from U-937 cells untreated or treated with PDTC for different times. A 0.8-kb cDNA fragment of the human CD11c gene was used as a probe. Hybridization with the beta-actin is included as a control. B, luciferase-based recombinant plasmids harboring different regions of CD11c gene promoter were transiently transfected into U-937 cells and seeded in the absence or presence of PDTC and PMA. After 13 h of treatment, luciferase activity was measured in extracts from lysed cells. Fold inductions of luciferase activity in PDTC or PMA treated versus untreated cells are shown. Results are representative of four independent experiments that yielded substantially the same results. Location of consensus binding sites for AP-1, Sp1, Oct-1, and AP-2, as well as the major transcription start site (+1), are indicated.



To further investigate the effect of PDTC on CD11c gene transcription, we transfected U-937 cells with reporter plasmids containing the regions of the CD11c promoter spanning from -361 to +40, -253 to +40, and -160 to +40 (López-Cabrera et al., 1993). All of these constructs displayed basal promoter activity that was clearly increased in PDTC-treated transfected cells (Fig. 4B). This inducible activity was qualitatively similar although less potent than that exerted by PMA, which was used as a positive control. The transfection of longer fragments of the CD11c gene promoter spanning from -640 to +40 and -960 to +40 yielded similar levels of induction (data not shown) suggesting that the cis-acting elements responsible for the transcriptional activation mediated by PDTC were located within the -160 to +40 proximal region of the CD11c promoter.

Nuclear Factor Binding to the CD11c Gene Proximal Promoter Region in Response to PDTC

Data base analysis of the nucleotide sequences within the -160 to +40 region indicated the presence of consensus motifs for binding of different transcription factors, such as AP-1, Sp1, AP-2, PU.1, and RARE sites (López-Cabrera et al., 1993). To identify the nuclear factors responsible for the activation of the CD11c promoter by PDTC, we used overlapping double-stranded oligonucleotides spanning through this region as probes for mobility shift assays. Sequences from -68 to -46, -136 to -99, -81 to -55, -39 to -8, -54 to -23, -19 to +11, and -109 to -81 of the CD11c promoter were analyzed for the binding of nuclear extracts from U-937 cells treated or not with PDTC by EMSA (Fig. 5A, and data not shown). We have found that the complex retarded by probe A (-68 to -46), which contains a functional AP-1 site, was substantially augmented, in a dose-dependent manner, in response to PDTC (Fig. 5A). This retarded complex was specifically competed by addition of an excess of unlabeled homologous oligonucleotide to the binding reaction, whereas an excess of heterologous oligonucleotide failed to compete this binding (data not shown). Specific protein-DNA complexes formed by incubation of nuclear extracts from untreated cells with the rest of oligonucleotide probes containing either Sp1 (Fig. 5A, probe B) or the putative binding sequences for Sp1 (probe C), PU.1 (probes D, E, F, and G), and RARE (E) remained unaffected when they were tested using nuclear extracts from PDTC-treated cells (data not shown). Finally, the most conclusive evidence showing that PDTC-induced nuclear factors bound to the AP-1 site were members of the Fos and Jun families of transcription factors was obtained by supershift assays adding specific antisera directed against members of both families to the binding reaction. Antibodies to Jun and Fos efficiently inhibited the formation of the specific complex (Fig. 5B).


Figure 5: Effects of PDTC on binding activity to the -68/-46 and -136/-99 regions of CD11c promoter and on the RNA levels of c-fos and c-jun. A, nuclear extracts prepared from U-937 cells untreated and treated for 6 h with PDTC (50 and 100 µM) were incubated with probes including the -68 to -46 and -136 to -99 regions (probes A and B) of the CD11c gene promoter. DNA-protein complexes were resolved by EMSA. A 30-fold molar excess of unlabeled homologous oligonucleotide was used as competitor in binding reactions. B, probe A, containing an AP-1 consensus site was incubated with nuclear extracts from PDTC (100 µM) treated cells in the presence of preimmune rabbit antiserum or rabbit antisera against Fos family (RR 26/8) or Jun family (6 36/6) members. C, Dot blot analysis was performed with total RNA isolated from U-937 untreated (C) or treated with PDTC 50 µM and PMA 20 ng/ml for the time points indicated. RNA was hybridized with cDNA probes of c-fos, c-jun, and beta-actin.



In order to better characterize the mechanism involved in the induction of AP-1 DNA binding activity mediated by PDTC, we examined the effect of the antioxidant on the steady state mRNA levels of c-jun and c-fos. We performed dot-blot analysis using RNA from cells treated with PDTC or PMA. PDTC strongly increased c-jun mRNA levels as early as 30 min of treatment, reaching its highest levels between 4 and 7 h. Similarly, the dithiocarbamate also induced an early expression of c-fos mRNA that declined after 2 h of treatment (Fig. 5C).

Role of AP-1 on CD11c Gene Promoter Activation by PDTC

To further determine the functional contribution of the AP-1 site in the activation of CD11c gene promoter by PDTC, we used the plasmids pCD11C160(-60mut)-Luc and pCD11C361(-60mut)-Luc, which contained a 3-base pair substitution within the AP-1 binding site (-61 to -54) in the context of the -160/+40 and -361/+40 fragments of the CD11c promoter (Fig. 6A). This 3-base pair substitution affected AP-1 binding activity, since oligonucleotides containing the mutated sequence failed to compete with the specific AP-1 complex generated with the radiolabeled wild type probe in EMSA (data not shown). In addition, the activities of the pCD11C160(-60mut)-Luc and pCD11C361(-60mut)-Luc mutated constructs in response to PDTC were significantly lower than those obtained with the wild type constructs (Fig. 6B). However, the mutated constructs displayed a similar fold induction than did the wild type constructs in response to butyrate, a very potent activator of CD11c promoter.^2 Hence, mutations of the AP-1 site did not indiscriminately block the transcriptional responsiveness of the CD11c promoter that remained inducible by other differentiation inducer. Taken together, our data indicated that the DTC-induced CD11c gene expression is regulated at the transcriptional level involving the functional activation of AP-1.


Figure 6: Role of AP-1 in CD11c gene promoter activity in response to PDTC. A, sequences of the wild type (white box) and mutated regions (black box) (-68 to -46) of the CD11c promoter. The substitutions introduced within the AP-1 site (-61 to -54) are indicated. B, recombinant wild type plasmids, containing -361/+40 and -160/+40 regions of CD11c gene promoter and the respective mutated plasmids, were transiently transfected into U-937 cells, and after 13 h of treatment with PDTC, luciferase activity was measured. Relative luciferase activity was expressed as fold induction over the activity of the promoterless plasmid pXP2 in untreated and treated cells. Results are representative of three independent experiments.




DISCUSSION

Alteration of the redox status of the cells by antioxidant agents such as DTCs, has previously been shown to interfere with the activity and expression of the transcription factors NFkappaB and AP-1, which appear to be involved in cell differentiation and activation processes (Baeuerle and Henkel, 1994). The results presented in this report show that DTCs simultaneously induce the expression of myeloid differentiation markers in U-937 cells and inhibit cell proliferation. To characterize the mechanisms responsible for DTC-mediated cell differentiation, we have analyzed as a model the activation of CD11c gene transcription. These studies suggest that PDTC induces the transcriptional activation of the CD11c gene through the activation of the AP-1 transcription factor.

The comparative analysis of differentiation markers induced by DTCs and PMA indicated that both elicit a similar pattern of cell surface antigen expression. In addition, PDTC and PMA induced the NSE enzymatic activity, inhibited cell growth, down-modulated c-myc RNA levels, and increased those of c-fos and c-jun. However, several lines of evidence indicate that both inducers act through different signaling mechanism. (i) Whereas the changes in the expression of myeloid surface antigens by PMA have been shown to be dependent on the activity of PKC (Bellón et al., 1994) (Fig. 3), those mediated by PDTC were not affected by the specific PKC inhibitor bisindolylmaleimide. In accordance, it has been previously shown that the treatment of Jurkat T cells with PDTC does not affect the activity of PKC (Meyer et al., 1993). (ii) PMA triggers strong homotypic aggregation, cell adhesion, and spreading to plastic surface (Collins, 1987; Miller et al., 1986; Nueda et al., 1995). In contrast, PDTC induced only a weak homotypic aggregation. These results also support that PKC-independent signals are mediating the effect of DTCs, since the aggregation and adhesion processes induced by PMA have been proposed to be dependent on a PKC-induced conformational change of the beta2 integrin molecules (Keizer et al., 1988). (iii) Flow cytometry analysis using dichlorofluorescein dye revealed that PMA induces an increase of the intracellular H(2)O(2) levels in U-937 cells whereas PDTC has the opposite effect. (^3)

Several antioxidants have been shown to influence the activity of the inducible transcription factors NFkappaB and AP-1 (Beg et al., 1993; Meyer et al., 1993; Schreck et al., 1992a, 1992b; Staal et al., 1990). In HeLa cells PDTC, N-Acetyl-L-Cysteine (NAC) and the antioxidative enzyme ADF/thioredoxin potently activates the transcription factor AP-1 involving induction of c-fos and c-jun (Meyer et al., 1993). Our results indicate that PDTC stimulates the surface expression of CD11c/CD18 (p150,95), increasing its alpha-subunit (CD11c) mRNA steady state levels by transcriptional mechanisms acting on the CD11c gene promoter. The induction of c-fos and c-jun mRNA levels by PDTC, as well as the presence of an AP-1 site at -60, the elimination of which greatly decreases the PDTC responsiveness of the CD11c promoter, supports an important role of AP-1 transcription factor in the activation and differentiation process elicited by DTCs. In this context, this transcription factor has been suggested to play a role in the myeloid differentiation triggered by different inducers such as PMA or etoposide (Bellón et al., 1994; Pérez et al., 1994). Furthermore, PMA has been shown to induce AP-1 DNA binding activity to the functional AP-1 site at -60 on the CD11c promoter, concomitant with the appearance of Fos protein detected by EMSA, while only Jun components, that account for the basal levels of AP-1, are detected in undifferentiated U-937 cells.^2 Thus, AP-1 may represent a transcription factor that can integrate different signals elicited by several differentiation agents that converge at this point. However, in order to explain the distinct patterns of differentiation observed, additional signaling different to AP-1 activation must be produced by the different inducers.

A thorough study of the nuclear factors that bind to the responsive region of the CD11c promoter spanning from -160 to +40, revealed that PDTC restrictively induced DNA binding activity to the AP-1 site. Hence, AP-1 is stimulated in a specific manner and can function as an antioxidant-responsive transcription factor in U-937 cells. Similarly, the genes of the antioxidative enzymes NAD(P)H:quinone oxidoreductase, EC 1.6.99.2, previously known as DT-diaphorase and the glutathione S-transferase Ya subunit, are controlled at the transcriptional level through antioxidant responsive elements in their promoter regions. These elements are required for the transcriptional activation mediated by several antioxidants (Rushmore et al., 1991). Since antioxidants can induce a hypoxic status in the cells, it is noteworthy that the DT-diaphorase gene is transcriptionally activated under hypoxic conditions in human colon cancer cells. Moreover, this effect involves early induction of jun family genes followed by a latter elevation of c-fos m-RNA levels (Yao et al., 1994). Interestingly, the gene promoter of the DT-diaphorase contains an AP-1 motif that has been shown to be functionally involved in the transcriptional induction of the gene by polycyclic aromatic hidrocarbons and phenolic antioxidants (Li and Jaiswal, 1992). Mutation of this site results in the loss of basal and induced transcriptional activity of the promoter. As shown in this paper, the AP-1 site of the CD11c promoter behaves in a similar fashion to that of the DT-diaphorase promoter and could, therefore, be considered an antioxidant responsive element. In this regard, it would be interesting to study whether the activation of the AP-1 transcription factor under hypoxic conditions could trigger the expression of CD11c.

Finally, DTCs are drugs that have already been pharmacologically used in heavy metal poisoning and AIDS treatment (Lang et al., 1985; Sunderman et al., 1967). It will be important to determine whether the effects of the DTCs that we have described in U-937 and HL-60 cells are also operative in leukemic cells derived from patients. In this regard, retinoic acid has been used in the treatment of patients with acute promyelocytic leukemia yielding a high rate of transient clinical remissions (Chen et al., 1991; Warrel et al., 1991). However, after prolonged periods of treatment, resistance to RA appears and the disease is reactivated (Delva et al., 1993). The effects of DTCs on myeloid cell differentiation supports a therapeutical potential of these agents in bone marrow-derived malignancies. Future experiments on fresh leukemic cells will aid in the elucidation of this interesting matter.


FOOTNOTES

*
This work was supported in part by grants from Ministerio de Educación y Ciencia (MEC) of Spain CICYT SAF 94.0817 and Comunidad Autónoma de Madrid (CAM) AE 60/94 (to J. M. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a fellowship from the Ministerio de Educación y Ciencia.

Supported by a fellowship from Comunidad Autónoma de Madrid.

**
To whom correspondence should be addressed: Centro de Biología Molecular, CSIC-UAM, Facultad de Ciencias, Cantoblanco, Madrid 28049, Spain. Tel.: 34-1-3978413; Fax: 34-1-3092496.

(^1)
The abbreviations used are: ROI, reactive oxygen intermediate; DTC, dithiocarbamate; PDTC, pyrrolidine dithiocarbamate; DDTC, diethyl dithiocarbamate; PMA, phorbol 12-myristate 13-acetate; mAb, monoclonal antibody; NSE, nonspecific esterase; EMSA, electrophoretic mobility shift assay; PKC, protein kinase C; kb, kilobase pair(s).

(^2)
López-Rodríguez, C., Nelemans, H. K., and Corbí, A. L.(1996) J. Immunol., (in press).

(^3)
J. Aragonés, and J. M. Redondo, unpublished results.


ACKNOWLEDGEMENTS

We are grateful to Dr. R. González-Amaro for advice and help refining the manuscript and Drs. J. González-Castaño, A. López Rivas, C. Muñoz, M. López-Botet, F. Sánchez-Madrid, M. Fresno, B. Alarcón, and A. Alfranca for helpful discussions and critical reading of the manuscript. We also thank Dr. P. Aller for advice and helpful discussions, Dr. R. Bravo for generous gift of antisera against Fos and Jun family members, Dr. P Angel for providing us the plasmids RSVc-fos and RSVc-jun, and Dr. M. Montoya and M. Vitón for excellent technical assistance.


REFERENCES

  1. Abate, C., Patel, L., Rauscher, F. J., III, and Curran, T. (1990) Science 249, 1157-1161 [Medline] [Order article via Infotrieve]
  2. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179 [CrossRef][Medline] [Order article via Infotrieve]
  3. Beg, A. A., Finco, T. S., Nanterment, P. V., and Baldwin, A. S., Jr. (1993) Mol. Cell. Biol. 13, 3301-3310 [Abstract]
  4. Bellón, T., López-Rodríguez, C., Rubio, M. G., Jochems, G., Bernabeu, C., and Corbí, A. L. (1994) Eur. J. Immunol. 24, 41-47 [Medline] [Order article via Infotrieve]
  5. Brenner, D. A., O'Hara, M., Angel, P., Chojkier, M., and Karin, M. (1989) Nature 337, 661-663 [CrossRef][Medline] [Order article via Infotrieve]
  6. Cabañas, C., Sánchez-Madrid, F., Bellón, T., Figdor, C. G., Te Velde, A. A., Fernández, J. M., Acevedo, A., and Bernabeu, C. (1989) Eur. J. Immunol. 19, 1373-1378 [Medline] [Order article via Infotrieve]
  7. Cabañas, C., Sánchez-Madrid, F., Aller, P., Yague, E., and Bernabeu, C. (1990) Eur. J. Biochem. 191, 599-604 [Abstract]
  8. Chen, Z. X., Xue, Y. Q., Zang, R., Tao, R. F., Xia, X. M., Li, C., Wang, W., Zu, W. Y., Yao, X. Z., and, Ling, B. J. (1991) Blood. 78, 1413-1419 [Abstract]
  9. Collins, S. J. (1987) Blood. 70, 1233-1244 [Abstract]
  10. Corbí, A. L., Miller, L. J., O'Connor, K., Larson, R. S., and Springer, T. A. (1987) EMBO J. 6, 4023-4028 [Abstract]
  11. Cotter, T. G., Fernandes, R. S., Verhaegen, S., and McCarthy, J. V. (1994) Immunol. Rev. 142, 93-112 [Medline] [Order article via Infotrieve]
  12. Datta, R., Hallahan, D. E., Kharbanda, S. M., Rubin, E., Sherman, M. L., Huberman, E., Weichselbaum, R. R., and Kufe, D. W. (1992) Biochemistry 31, 8300-8306 [Medline] [Order article via Infotrieve]
  13. Delva, L., Cornic, M., Balitrand, N., Guidez, F., Miclea, J. M., Delmer, A., Teillet, F., Fenaux, P., Castaigne, S., Degos, L., and Chomienne, C. (1993) Blood 82, 2175-2181 [Abstract]
  14. Devary, Y., Gottlieb, R. A., Lau, L. F., and Karin, M. (1991) Mol. Cell. Biol. 11, 2804-2811 [Medline] [Order article via Infotrieve]
  15. Dood, T. C., Cohen, M. S., Newman, S. L., and Gray, T. K. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 7538-7541 [Abstract]
  16. Dustin, M. L., Rothlein, R., Bham, A. K., Dinarello, C. A., and Springer, T. A. (1986) J. Immunol. 137, 245-254 [Abstract/Free Full Text]
  17. Ferreira, O. C., Valinsky, J. E., Sheridan, K., Wayner, E. A., Bianco, C., and García-Pardo, A. (1991) Exp. Cell Res. 193, 20-26 [Medline] [Order article via Infotrieve]
  18. Hass, R., Bartels, H., Topley, N., Hadam, M., Köhler, L., Goppelt-Strübe, M., and Resch, K. (1989) Eur. J. Cell Biol. 48, 282-293 [Medline] [Order article via Infotrieve]
  19. Hogg, N., Takacs, L., Palmer, D. G., Selvendran, Y., and Allen, C. (1986) Eur. J. Immunol. 16, 240-248 [Medline] [Order article via Infotrieve]
  20. Hynes, R. O. (1992) Cell 69, 11-25 [Medline] [Order article via Infotrieve]
  21. Keizer, G. D., Visser, W., Vliem, M., and Figdor, C. G. (1988) J. Immunol. 140, 1393-1400 [Abstract/Free Full Text]
  22. Lang, J. M., Oberling, F., Aleksijevic, A., Falkenrodt, A., and Mayer, S. (1985) Lancet 8463, 1066
  23. Li, Y., and Jaiswal, A. K. (1992) J. Biol. Chem. 267, 15097-15104 [Abstract/Free Full Text]
  24. López-Cabrera, M., Nueda, A., Vara, A., Garcia-Aguilar, J. G., Tugores, A., and Corbí, A. L. (1993) J. Biol. Chem. 268, 1187-1193 [Abstract/Free Full Text]
  25. López Guerrero, J. A., Redondo, J. M., Alarcón, B., Sánchez-Madrid, F., Rodríguez Moya, M., Ortiz de Landázuri, M., Bernabeu, C., and Fresno, M. (1989) Immunology 66, 252-257 [Medline] [Order article via Infotrieve]
  26. Meyer, M., Schreck, R., and Baeuerle, P. A. (1993) EMBO J. 12, 2005-2015 [Abstract]
  27. Miller, L. J., Schwarting, R., and Springer, T. A. (1986) J. Immunol. 137, 2891-2900 [Abstract/Free Full Text]
  28. Minta, O. J., and Pambrum, L. (1985) Am. J. Pathol. 119, 111-126 [Abstract]
  29. Muñoz, E., Zubiaga, A. M., and Huber, B. T. (1992) Eur. J. Immunol. 22, 2101-2106 [Medline] [Order article via Infotrieve]
  30. Nueda, A., López-Rodríguez, C., Rubio, M. A., Sotillos, M., Postigo, A., del Pozo, M. A., Vega, M. A., and Corbí, A. L. (1995) Cell. Immunol. 164, 163-169 [CrossRef][Medline] [Order article via Infotrieve]
  31. Osborn, L., Kunkel, S., and Nabel, G. J. (1989) Proc. Natl. Acad. U. S. A. 86, 2336-2340 [Abstract]
  32. Pérez, C., Vilaboa, N. E., and Aller, P. (1994) Cell Growth Differ. 5, 949-955 [Abstract]
  33. Postigo, A., Corbí, A. L., Sánchez-Madrid, F., and de Landázuri, M. O. (1991) J. Exp. Med. 174, 1313-1322 [Abstract]
  34. Pulido, R., Elices, M. J., Campanero, M. R., Osborn, L., Schiffer, S., García-Pardo, A., Lobb, R., Hemler, M. E., and Sánchez-Madrid, F. (1992) J. Biol. Chem. 266, 10241-10245 [Abstract/Free Full Text]
  35. Ralph, P., Harris, P. E., Punjabi, C. J., Welte, K., Litcofsky, P. B., Ho, M. K., Rubin, B. Y., Moore, M. A. S., and Springer, T. A. (1983) Blood 62, 1169-1175 [Abstract]
  36. Redondo, J. M., Pfhol, J. L., and Krangel, M. S. (1991) Mol. Cell. Biol. 11, 5671-5680 [Medline] [Order article via Infotrieve]
  37. Rius, C., Cabañas, C., and Aller, P. (1990) Exp. Cell Res. 188, 129-134 [Medline] [Order article via Infotrieve]
  38. Rovera G., Santoli, D., and Damsky, C. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 2779-2783 [Abstract]
  39. Rushmore, T. H., Morton, M. R., and Pickett, C. B. (1991) J. Biol. Chem. 266, 11632-11639 [Abstract/Free Full Text]
  40. Sambrook, J., Fristsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  41. Schenk, H., Matthias, K., Erdbrügger, W., Dröge, W., and Schulze-Osthoff, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1672-1676 [Abstract]
  42. Schreck, R., Rieber, P., and Baeuerle, P. A. (1991) EMBO J. 10, 2247-2258 [Abstract]
  43. Schreck, R., Meier, B., Männel, D. N., Dröge, W., and Baeuerle, P. A. (1992a) J. Exp. Med. 175, 1181-1194 [Abstract]
  44. Schreck, R., Alberman, K., and Baeuerle, P. A. (1992b) Free Radical Res. Commun. 17, 221-237 [Medline] [Order article via Infotrieve]
  45. Schütze, S., Scheurich, P., Schlüter, C., Ucer, U., Pfizenmaier, K., and Krönke, M. (1988) J. Immunol. 140, 3000-3005 [Abstract/Free Full Text]
  46. Staal, F. J. T., Roederer, M., Herzenberg, L. A., and Herzenberg, L. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9943-9947 [Abstract]
  47. Sunderman, F. W., Paynter, O. E., and George, R. B. (1967) Am. J. Med. Sci. 254, 24-34 [Medline] [Order article via Infotrieve]
  48. Sundström, C., and Nilsson, K. (1976) Int. J. Cancer 17, 565-577 [Medline] [Order article via Infotrieve]
  49. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771-15781 [Abstract/Free Full Text]
  50. Warrel, R., Frankel, S., Miller, W., Scheiber, D., Itri, L., Hittleman, W., Vyas, R., Andreef, M., Tafuri, A., Jakuboski, A., Gabrilove, J., Gordon, M., and Dmitrovski, E. (1991) N. Engl. J. Med. 324, 1385-1393 [Abstract]
  51. Yao, K.-S., Xanthoudakis, S., Curran, T., and O'Dwyer, P. J. (1994) Mol. Cell. Biol. 14, 5997-6003 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.